Neumora reports NMRA-215 preclinical data: up to 19% monotherapy weight loss, 26% with semaglutide

Neumora Therapeutics, Inc.

NMRA-215 showed class-leading 19% weight loss as monotherapy with semaglutide-like induction in DIO mice.
Combination with high-dose semaglutide achieved up to 26% weight loss, best-in-class vs. NLRP3 inhibitors.
Preclinical data support potential as oral, brain-penetrant NLRP3 inhibitor for obesity.
Neumora plans to initiate Phase 1 clinical study for NMRA-215 in Q1 2026.
Additional data to be presented at virtual R&D day on October 27, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.